Bio-Connect

InVivoMAb anti-mouse/human IL-5

BE0198
Bio X Cell
ApplicationsNeutralisation/Blocking, Other Application
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoMAb anti-mouse/human IL-5
  • Delivery Days Customer
    7
  • Applications
    Neutralisation/Blocking, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    TRFK5
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Rat
  • Isotype
    IgG1
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016,22(12):1402-1410. doi: 10.1038/nm.4200
    Read this paper
  • Griseri T, Arnold IC, Pearson C, et al. Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis. Immunity. 2015,43(1):187-99. doi: 10.1016/j.immuni.2015.07.008
    Read this paper
  • Sanfilippo AM, Furuya Y, Roberts S, et al. Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages. Infect Immun. 2015,83(7):2976-83. doi: 10.1128/IAI.00142-15
    Read this paper
  • Shi Y, Tsuboi N, Furuhashi K, et al. Pristane-induced granulocyte recruitment promotes phenotypic conversion of macrophages and protects against diffuse pulmonary hemorrhage in Mac-1 deficiency. J Immunol. 2014,193(10):5129-39. doi: 10.4049/jimmunol.1401051
    Read this paper
  • Weng M, Baron DM, Bloch KD, et al. Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2011,301(6):L927-36. doi: 10.1152/ajplung.00049.2011
    Read this paper